This radiopharmaceutical is 2-deoxy-2-fluoro-D-glucose radiolabeled with 18F. 18F-FDG is a high affinity substrate for glucose transporter type 1 (GLUT1) that is strongly overexpressed in many types of lethal cancer that characteristically use increased amounts of glucose. After uptake 18F-FDG is bound with the cell allowing visualisation of abnormal cancer cell glucose metabolism throughout the body when combined with positron emitting tomography (PET) imaging. Cancers that are invisible to all other forms of imaging are often detected using 18F-FDG PET imaging has led to widespread use of this technique for guiding treatment in many different cancer indications and some government assistance is provided through the Medical Benefits Scheme.
This radiopharmaceutical is a urea-based molecule radiolabeled with 18F. 18F-DCFPyL binds to the enzymatic site of prostate specific membrane antigen (PSMA) inhibiting PSMA activity and is strongly internalised. Very often PSMA is strongly overexpressed in prostate cancer cells, particularly more aggressive forms including metastatic and androgen resistant tumours, but is present in much lower amounts in most normal tissues.
When combined with positron emitting tomography (PET) imaging 18F-DCFPyL, provides highly specific and sensitive visualisation of sites of prostate cancer throughout the body. A large body of evidence indicates that PSMA PET imaging, including with 18F-DCFPyL, provides unique information for guiding treatment decisions in men with prostate cancer, particularly in the setting of primary staging of intermediate and high risk prostate cancer and Biochemical Recurrence.
Cyclotek is undertaking and supporting further clinical trials with the use of 18F-DCFPyL.
This radiopharmaceutical is an estradiol analogue radiolabeled with 18F. In normal women estradiol is a major form of estrogen that acts via estrogen receptors (ER) to regulate a range of normal cellular functions in the breast and reproductive tissues. A large percentage of breast cancers overexpress ER and diminishing the stimulatory effects of estrogen is a common form or breast cancer treatment. 18F-FES maintains a high affinity for ER and so facilitates high specificity visualization of ER-positive tissues and particularly tumours throughout the body when combined with positron emitting tomography (PET )imaging.
Cyclotek is working with and supporting clinical investigators to better define the clinical role of 18F-FES in the management of breast cancer patients.
This radiopharmaceutical is the amino acid analog ethyl tyrosine radiolabeled with 18F Fluorine. 18F-FET is a substrate for the Large Amino Acid Transporter 1 (LAT1) that is overexpressed in many tumour cells. 18F-FET is actively transported into cells according to their LAT1 concentration but neither incorporated into proteins nor readily degraded and therefore able to be transported out the cell again. 18F-FET can be transported across the blood brain barrier and has been shown to have high retention in gliomas across the spectrum of tumour grades relative to normal brain uptake. Research has shown that 18F-FET combined with positron emitting tomography (PET )imaging can provide unique diagnostic information and treatment guidance for a range of clinical indications involving glioma management.
18F-FDG is also actively concentrated by brain tumours at levels that correlate with the grade of the glioma, however the high uptake of 18F-FDG in normal brain limits the use of this radiopharmaceutical for assessing gliomas.
Cyclotek is working with and supporting clinical investigators to better define the clinical role of 18F-FET in glioma patient management.
This radiopharmaceutical is the sodium salt of 18F Fluoride that allows investigation of bone mineralisation with positron emitting tomography (PET ) imaging. Almost all Na18F delivered in the blood is extracted by bone in a single pass so this tracer is a reliable indicator of relative regional bone blood flow. Na18F passes from the blood to the bone extracellular fluid and into the shell of bound water surrounding each hydroxyapatite crystal. Chemisorption follows whereby 18F exchanges with OH on the surface of the hydroxyapatite crystal to form fluorapatite. Na18F uptake and retention in bone depends on the area of “exposed” bone surface which is larger in a variety of benign and malignant bone disorders giving rise to regions of high Na18F uptake or “hot spots”.
Na18F PET bone scans provide similar information to conventional bone scans with greater spatial and contrast resolution and with a much shorter delay between administration of the radiopharmaceutical and scanning leading to a shorter overall procedure time.
PET images may include the whole skeleton or only symptomatic regions.
This product is available only in New Zealand.
[contact-form-7 id=”714″ title=”Update Form”]